BioSpace News Archive

DSwiss, Inc announced that it has ventured into the field of direct-to-consumer DNA Testing.

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (“PAD”), today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, their option to purchase an additional 1,000,000 shares of the Company’s common stock at a price of $0.47 per share

A national leader in pediatric oncology research and treatment, Dr. Laetsch will also lead CHOP’s Developmental Therapeutics Program

City of Hope is investigating an innovative treatment for cancer patients with COVID-19 by repurposing leflunomide, an anti-inflammatory drug for rheumatoid arthritis that is inexpensive and has few serious side effects, in a new clinical trial.

Applied UV, Inc. announced in connection with its previously announced initial public offering of its common stock, the exercise by Network 1 Financial Securities, Inc., the managing underwriter of its overallotment option to purchase an additional 150,000 shares of common stock at a price of $5.00 per share less the underwriting discount.

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that management will participate in the following upcoming virtual investor conferences: